Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.635 USD | +0.94% | -1.26% | -19.48% |
Financials (USD)
Sales 2024 * | 538K | Sales 2025 * | 675K | Capitalization | 25.32M |
---|---|---|---|---|---|
Net income 2024 * | -37M | Net income 2025 * | -48M | EV / Sales 2024 * | 47.1 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 37.5 x |
P/E ratio 2024 * |
-0.8
x | P/E ratio 2025 * |
-1.01
x | Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.77% |
Latest transcript on Oncternal Therapeutics, Inc.
1 day | +0.94% | ||
1 week | -1.26% | ||
Current month | +3.91% | ||
1 month | +0.17% | ||
3 months | -12.60% | ||
6 months | +43.96% | ||
Current year | -19.48% |
Managers | Title | Age | Since |
---|---|---|---|
James Breitmeyer
FOU | Founder | 70 | 96-12-31 |
Richard Vincent
DFI | Director of Finance/CFO | 61 | 17-03-31 |
Salim Yazji
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-05-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hale
FOU | Founder | 75 | 96-12-31 |
Dan Kisner
BRD | Director/Board Member | 77 | 19-06-06 |
Rosemary Mazanet
BRD | Director/Board Member | 67 | 21-01-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 8.635 | +0.94% | 997 |
24-05-08 | 8.555 | +0.41% | 737 |
24-05-07 | 8.52 | -5.33% | 11,112 |
24-05-06 | 9 | +2.92% | 3,481 |
24-05-02 | 8.745 | +6.00% | 10,172 |
Delayed Quote Nasdaq, May 09, 2024 at 03:37 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.48% | 25.32M | |
+24.34% | 46.71B | |
+48.83% | 41.8B | |
-1.02% | 41.52B | |
-5.86% | 29.55B | |
+11.07% | 25.78B | |
-20.88% | 19.26B | |
+3.14% | 12.14B | |
-2.28% | 12.08B | |
+30.58% | 11.98B |
- Stock Market
- Equities
- ONCT Stock